| European Case Law Identifier: | ECLI:EP:BA:2017:T048816.20170201 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 01 February 2017 | ||||||||
| Case number: | T 0488/16 | ||||||||
| Application number: | 00922102.9 | ||||||||
| IPC class: | A61K 31/426 C07C 237/40 C07D 213/81 C07D 213/82 C07D 231/38 C07D 233/90 C07D 239/42 C07D 263/48 C07D 277/56 C07D 409/12 C07D 417/12 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | ||||||||
| Applicant name: | Bristol-Myers Squibb Holdings Ireland | ||||||||
| Opponent name: | Isenbruck Bösl Hörschler LLP APOTEX INC. Actavis Group PTC ehf Generics [UK] Limited |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Inventive step - (no) No plausible solution of the technical problem Solution to less ambitiously defined problem obvious Referral to the Enlarged Board of Appeal - (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t160488eu1.html
Date retrieved: 17 May 2021